Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers
Alina Ciammaichella, Francesca Puca, Danilo Fabbrini et al. · Journal of Medicinal Chemistry · 2026
SHP2 (Src homology 2 (SH2)-containing protein tyrosine phosphatase 2) is a tyrosine phosphatase that plays a critical role in numerous physiological and pathological cellular processes, including cell proliferation, survival, and migration through the regulation of multiple signaling pathways, such as RAS-RAF-mitogen-activated protein kinase, phosphatidylinositol 3-kinase (PI3K)-AKT, Janus tyrosine kinase (JAK), and signal transducer and activator of transcription pathways (STAT) in response to cytokines and growth factors. Through extensive structure-based optimization, we identified I-0436650, a preclinical candidate with an excellent pharmacological profile. I-0436650 is a low nanomolar allosteric inhibitor of human wild-type (wt) SHP2 and strongly inhibits ERK phosphorylation in cells. It exhibits antiproliferative activity in EGFR- and RAS-dependent cell lines, suppresses tumor growth as a single agent in xenograft models, and delays tumor relapse when combined with inhibitors of the same pathway, demonstrating the potential of vertical inhibition strategies.
Cited by 0 works. doi:10.1021/acs.jmedchem.6c01182
Authors
- Danilo Fabbrini
- Pietro Randazzo
- Ilaria Rossetti
- Alessio Sferrazza
- Federica Ferrigno
- Alessandro Grillo
- Esther Torrente
- Costanza Iaccarino
- Jérôme Amaudrut
- Antonella Cellucci
- Annalise Di Marco
- Simone Palombo
- Simone Esposito
- Monica Bisbocci
- Maria Vittoria Orsale
- Martina Nibbio
- Antonino Missineo
- Francesco Scalabrì
References
- Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
- Crystal Structure of the Tyrosine Phosphatase SHP-2
- Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
- PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
- The tyrosine phosphatase Shp2 (PTPN11) in cancer
- Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
- Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
- Molecular mechanism of SHP2 activation by PD-1 stimulation
- Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
- Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors